MetaVia (NASDAQ:MTVA) Raised to “Hold” at Wall Street Zen

MetaVia (NASDAQ:MTVA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other analysts have also recently issued reports on MTVA. HC Wainwright cut their target price on MetaVia from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $26.50.

MetaVia Stock Performance

MTVA stock opened at $1.22 on Friday. The firm’s 50-day moving average price is $1.81 and its two-hundred day moving average price is $6.79. MetaVia has a 12-month low of $1.21 and a 12-month high of $23.10. The stock has a market capitalization of $2.68 million, a price-to-earnings ratio of -0.15 and a beta of 0.34.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.